Mironid raised $46 million in a Series B as its lead program, MR-L45, moved into clinical development for autosomal dominant polycystic kidney disease. The company said MR-L45 is an orally available small molecule designed to address the disease during early clinical evaluation. The financing supports the transition from discovery into clinical dosing and associated translational work to establish pharmacology, safety, and biomarker relationships in patients. For ADPKD, where disease modification remains an active therapeutic race, new oral candidates continue to draw attention due to the chronic treatment profile. Investors’ backing also signals continued faith in mechanism-driven small molecules targeting core pathways of cyst growth and progression rather than only symptom management.